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Introduction {#sec001}
============

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension (PH) caused by persistent thromboemboli of the pulmonary arteries. Various etiological factors, including infection, inflammation, genetic susceptibilities, and insufficient angiogenesis \[[@pone.0211377.ref001]\], have been discussed as important pathogenetic factors \[[@pone.0211377.ref002]\]. However, the etiology of CTEPH is not completely understood, and disease-specific, non-invasive biomarkers have not been identified.

Circulating autoantibodies have been detected in patients with several cardiovascular diseases, such as atherosclerosis \[[@pone.0211377.ref003], [@pone.0211377.ref004]\] and other cardiovascular diseases, including coronary artery diseases\[[@pone.0211377.ref005]\]. As a typical example, anti-phospholipid antibodies reportedly enhance the uptake of oxidized LDL by macrophages, which leads to foam cell formation \[[@pone.0211377.ref005]--[@pone.0211377.ref007]\]. Recently, we established the auto-antibody screening method using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) and found that anti-adiponectin antibody levels were significantly higher in patients with coronary artery disease, cerebral infarction and diabetes mellitus than in HDs \[[@pone.0211377.ref008]\]. However, autoantibodies in the context of CTEPH and pulmonary arterial hypertension (PAH) have not yet been thoroughly explored.

In the present study, we comprehensively screened autoantigens recognized by IgG antibodies in the sera of patients with CTEPH using a protein array. We then selected and identified the autoantibodies elevated in the sera of CTEPH patients and also investigated whether or not PAH patients had the same autoantibodies.

Materials and methods {#sec002}
=====================

Ethical statement {#sec003}
-----------------

The protocol for the analysis of the sera from CTEPH and PAH patients was approved by the Local Ethical Review Board of the Chiba University Graduate School of Medicine (approval number 1248). The protocol for the serum analysis in healthy donors (HDs) and the patients with sleep apnea syndrome (SAS) was also approved by the Local Ethical Review Board of the Chiba University Graduate School of Medicine (approval number 973). Written informed consent was obtained from all participating patients before sera were collected.

Patients and healthy donor sera {#sec004}
-------------------------------

We collected serum samples from patients diagnosed with CTEPH and PAH at Chiba University Hospital between 2001 and 2015. Serum samples were collected from HDs who underwent annual medical checkups at Port Square Kashiwado Clinic. We also collected serum samples from patients with SAS, as previously reported \[[@pone.0211377.ref009]\] \[[@pone.0211377.ref010]\]. Each serum sample was centrifuged at 3,000 × *g* for 10 min at room temperature, and then the supernatant was stored at -80°C until use (no other freeze-thaw cycles).

The ProtoArray human protein microarrays analysis {#sec005}
-------------------------------------------------

Serum samples from 5 CTEPH patients and 5 HDs were profiled on a ProtoArray Human Protein Microarrays v5.1 containing 9,375 human proteins. The serum samples were profiled at a 1:500 dilution, utilizing one ProtoArray Human Protein Microarray per sample. Alexa Fluor 647-anti-human IgG detection reagent was used to quantify the IgG level of associated auto-antibodies. Pairwise comparisons were made between the two sample populations. Assays were performed by Thermo Fisher Scientific (Waltham, MA, USA) according to the manufacturer's instructions.

Epitope prediction and peptide synthesis {#sec006}
----------------------------------------

Possible epitope sites in the selected antigenic proteins were predicted using the software program ProPred (<http://www.imtech.res.in/raghava/propred/>) as described previously \[[@pone.0211377.ref011]\].

Amplified luminescence proximity homogeneous assay (AlphaLISA) {#sec007}
--------------------------------------------------------------

AlphaLISA was performed in 384-well microtiter plates (white opaque ProxiPlate PerkinElmer, Waltham, MA, USA) containing 2.5 μL of 1/100-diluted sera and 2.5 μL of GST or a GST-fusion protein (10 μg/mL) in AlphaLISA buffer (25 mM 4-\[2-hydroxyethyl\]-1-piperazineethanesulfonic acid \[HEPES\], pH 7.4, 0.1% casein, 0.5% Triton X-100, 1 mg/mL dextran-500, and 0.05% Proclin-300). The resulting reaction mixture was incubated at room temperature for 6 to 8 h. After incubation, anti-human IgG-conjugated acceptor beads (2.5 μL of 40 μg/mL) and streptavidin-conjugated donor beads (2.5 μL of 40 μg/mL) were added, and the samples were subjected to an additional 7 to 21 days of incubation at room temperature in the dark. The chemical emissions of samples were read on an EnSpire Alpha microplate reader (PerkinElmer). Specific reactions were calculated by subtracting the alpha values of buffer control samples from those of samples containing biotinylated peptides. The details have been described previously \[[@pone.0211377.ref009], [@pone.0211377.ref011]--[@pone.0211377.ref014]\].

Statistical analyses {#sec008}
--------------------

All statistical analyses were performed with a commercially available software program (JMP 10.0.2, Japanese version; SAS Institute Tokyo, Japan). The results are expressed as the mean ± standard deviation for continuous variables and as the number and percentage for categorical variables unless otherwise indicated. Comparisons between two groups were performed by Mann-Whitney U test, correlation analysis between two continuous variables were performed by Spearman's correlation analysis, and multiple comparisons were performed by Steel-Dwass test.

Results {#sec009}
=======

Initial screening of CTEPH-specific antigens by a protein array {#sec010}
---------------------------------------------------------------

Using a ProtoArray loaded with 9375 proteins, we examined the sera from 5 CTEPH patients and 5 HDs to identify CTEPH-associated antigens. We selected the antigens for which the absorbance ratio (CTEPH:HD) exceeded 1.5. As a result, the 34 proteins that were more strongly recognized by IgG antibodies in the sera of CTEPH patients than in HDs were selected ([Table 1](#pone.0211377.t001){ref-type="table"}).

10.1371/journal.pone.0211377.t001

###### Protein array-selected antigens recognized by serum antibodies of CTEPH patients.

![](pone.0211377.t001){#pone.0211377.t001g}

  Name       
  ---------- ----------
  GATA3      C12orf45
  NOL12      APOBEC4
  MGRN1      LASP1
  FSTL4      AIF1
  C11orf54   STAU1
  C9orf163   EXD2
  C14orf93   TSC22D3
  TNFSF13    Bystin
  NCF4       XTP3TPA
  LCORL      NR0B1
  HNRPA0     MYL2
  MXI1       PHAX
  PDGFRA     SCD
  COMMD10    FGF16
  CASK       FGF1
  PSMA4      IFNG
  TCN2       MAPKAPK3

List of protein antigens selected from the first screening using ProtoArray with sera from CTEPH patients and HDs.

Second screening using crude peptides {#sec011}
-------------------------------------

The amino acid sequence of the 63 peptides shown in [Table 2](#pone.0211377.t002){ref-type="table"} were predicted as epitope sites of the 34 candidate antigen proteins selected in the first screening using ProtoArray.

10.1371/journal.pone.0211377.t002

###### Amino acid sequences of synthetic peptides used for the second screening.

![](pone.0211377.t002){#pone.0211377.t002g}

  No.   Name              Sequence               No.   Name            Sequence
  ----- ----------------- ---------------------- ----- --------------- ----------------------
  1     bGATA3-12         `RNSVEIKKKLGLIFKWTN`   33    bC12orf45-106   `PHSKVIQMDVALFEMNQS`
  2     bNOL12-88         `LVTAKTESVQYDHPNHTV`   34    bAPOBEC4-175    `RSLASLWPRVVLSPISGG`
  3     bMGRN1-60         `LNFLGSRPVQFPYVTPAP`   35    bAPOBEC4-312    `KPRNIVRHLNMPQMSFQE`
  4     bMGRN1-194        `RGVFPVVIQAVVDEGDVV`   36    bAPOBEC4-331    `KDLGRLPTGRSVEIVEIT`
  5     bMGRN1-245        `RVSYLLQEIYGIENKNNQ`   37    bLASP1-61       `SFTMVADTPENLRLKQQS`
  6     bFSTL4-147        `RLKNVLLALQTRLQPLQE`   38    bAIF1-55        `MMLGKRSAILKMILMYEE`
  7     bFSTL4-234        `TLREFYIAFQVVQLSLAP`   39    bSTAU1-131      `HMKNFVTKVSVGEFVGEG`
  8     bFSTL4-509        `VRNRYIYVAQPALSRVLV`   40    bSTAU1-165      `LEELKKLPPLPAVERVKP`
  9     bFSTL4-526        `VVDIQAQKVLQSIGVDPL`   41    bSTAU1-442      `CSSQPPLISHGIGKDVES`
  10    bC11orf54-70      `PLVNQKKVYDLNKIAKEI`   42    bEXD2-60        `GCLDLRYLAMRQRNNLLC`
  11    bC9orf163-64      `RRLVREGVISVPRQQGRR`   43    bEXD2-307       `KNVIPHEYRKHFPIEMKD`
  12    bC14orf93-198     `YRLFANRSSIMRHFGPED`   44    bEXD2-446       `GLRSLMQLESRWRQHFLD`
  13    bTNFSF13-49       `LTQQTELQSLRREVSRLQ`   45    bTSC22D3-3      `LVKNHLMYAVREEVEILK`
  14    bTNFSF13-156      `RIQDAGVYLLYSQVLFQD`   46    bBystin-165     `TCTLREAIIVGSIITKCS`
  15    bTNFSF13-193      `RCIRSMPSHPDRAYNSCY`   47    bBystin-264     `KEALLELLRLQPHPQLSP`
  16    bNCF4-192         `KAGDVIFLLSRINKDWLE`   48    bXTP3TPA-22     `RFSFSPEPTLEDIRRLHA`
  17    bNCF4-298         `LSDEDVALMVRQARGLPS`   49    bNR0B1-273      `PCFQVLPLDQQLVLVRNC`
  18    bLCORL-159        `ELMKKMIRQFAIEYISKS`   50    bNR0B1-430      `NSTLFLLRFINANVIAEL`
  19    bHNRPA0-34        `TDCVVVVNPQTKRSRCFG`   51    bMYL2-114       `LKADYVREMLTTQAERFS`
  20    bHNRPA0-150       `DAADKAAVVKFHPIQGHR`   52    bPHAX-247       `ARVVRIIGNKKAIELLME`
  21    bMXI1-1           `MERVKMINVQRLLEAAEF`   53    bSCD-134        `LRLFLIIANTMAFQNDVY`
  22    bMXI1-85          `LCLERLKVLIPLGPDCTR`   54    bSCD-250        `TFLRYAVVLNATWLVNSA`
  23    bPDGFRA-10        `VLGCLLTGLSLILCQLSL`   55    bFGF16-92       `GILEFISLAVGLISIRGV`
  24    bPDGFRA-30        `ILPNENEKVVQLNSSFSL`   56    bFGF16-152      `YKHSDSERQYYVALNKDG`
  25    bCOMMD10-135 　   `ETVGWQLNLQMAHSAQAK`   57    bFGF1-58        `QLQLSAESVGEVYIKSTE`
  26    bCASK-34          `ETGQQFAVKIVDVAKFTS`   58    bFGF1-138       `THYGQKAILFLPLPVSSD`
  27    bCASK-103         `EIVKRADAGFVYSEAVAS`   59    bIFNG-32        `ILKNWKEESDRKIMQSQI`
  28    bCASK-254         `VRRMLMLDPAERITVYEA`   60    bIFNG-101       `TDLNVQRKAIHELIQVMA`
  29    bPSMA4-82         `DANVLTNELRLIAQRYLL`   61    bMAPKAPK3-146   `IMRDIGTAIQFLHSHNIA`
  30    bTCN2-2           `RHLGAFLFLLGVLGALTE`   62    bMAPKAPK3-275   `EDAKQLIRLLLKTDPTER`
  31    bTCN2-47          `LEHLNPSIYVGLRLSSLQ`   63    bMAPKAPK3-303   `WINQSMVVPQTPLHTARV`
  32    bTCN2-217         `YSTPLALQFLMTSPMRGA`                         

A total of 63 peptides were predicted to be epitopes derived from the 34 antigen proteins. The numbers in the peptide names represent the first amino acid number of the original protein. b: biotin-tag.

In the second screening, these 63 peptides were synthesized and used as antigens for the analysis of the serum antibody levels by AlphaLISA using sera from 48 CTEPH patients and 48 HDs. The levels of autoantibodies for nine peptides (No. 8, 10, 11, 19, 34, 35, 43, 46, 52) seemed higher in CTEPH patients than in HDs. We then performed an additional AlphaLISA analysis for those 9 autoantibodies using sera from 96 CTEPH patients and 96 HDs. These patients' basic characteristics are summarized in [Table 3](#pone.0211377.t003){ref-type="table"}.

10.1371/journal.pone.0211377.t003

###### Basic characteristics of patients whose sera were used in the AlphaLISA analysis.

![](pone.0211377.t003){#pone.0211377.t003g}

  ------------------------------------------------------------------------------------------------
                                                    CTEPH\        PAH\          Healthy Donor\
                                                    (n = 96)      (n = 65)      Control (n = 96)
  ------------------------------------------------- ------------- ------------- ------------------
  Sex (M:F)                                         19:77         18:47         53:43

  Age                                               59.9±11.2     51.0±17.6     56.2±9.28

  Height (cm)                                       157.6±10.0    159.1±8.9     164.1±8.55

  Body weight (kg)                                  56.3±12.0     57.3±14.9     63.4±11.8

  Body mass index                                   22.5±3.2      22.4±4.43     23.4±3.48

  Systolic blood pressure (mmHg)                    125.1±20.5    124.9±23.8    120.4±16.0

  Diastolic blood pressure (mmHg)                   75.3±13.8     70.6±11.5     78.1±11.4

  Mean pulmonary artery pressure (mmHg)             44.4±11.4     41.8±10.4     

  Pulmonary Vascular Resistance (dyne·sec·cm^-5^)   700.4±311.3   606.0±279.7   

  Cardiac output (L/min)                            4.22±1.17     4.67±1.27     

  Cardiac index (L/min/m^2^)                        2.95±0.77     2.86±0.78     

  WHO-FC (I:II:III:IV)                              0:47:47:2     0:47:18:0     
  ------------------------------------------------------------------------------------------------

Finally, the serum levels of autoantibodies against four peptides (No. 11, 35, 43, 52) seemed higher in CTEPH patients than in HDs ([Fig 1](#pone.0211377.g001){ref-type="fig"}) (A statistically significant difference in the auto-antibody level was noted for peptide No. 46 between the two groups; however, both groups had an extremely low alpha count, so the difference was not deemed to be etiologically significant).

![A comparison of the serum antibody levels against nine crude synthetic peptides between CTEPH patients and HDs.\
The results of the AlphaLISA analyses are shown. The Y-axis shows AlphaLISA counts which represent antibody levels (titer) in sera. The error bars show the mean and standard deviation. n.s.: not significant.](pone.0211377.g001){#pone.0211377.g001}

The selected antigenic peptides were as follows:

1.  No. 11: bC9orf163-64, biotinylated peptide of amino acid positions 64--84 of C9orf163

2.  No. 35: bAPOBEC4-312, biotinylated peptide of amino acid positions 312--329 of APOBEC4

3.  No. 43: bEXD2-307, biotinylated peptide of amino acid positions 307--324 of EXD2

4.  No. 52: bPHAX-247, biotinylated peptide of amino acid positions 247--264 of PHAX

Third screening using purified peptide {#sec012}
--------------------------------------

We then obtained purified antigenic peptides of bC9orf163-64, bAPOBEC4-312, bEXD2-307, and bPHAX-247, of which the purity was 98.10%, 95.59%, 95.43%, and 91.19%, respectively. We performed an AlphaLISA analysis using those 4 purified peptides with the same sera of 96 CTEPH patients and 96 HDs as a third screening. We detected significantly higher serum levels of antibodies against bEXD2-307 and bPHAX-247 in CTEPH patients than in HDs ([Fig 2](#pone.0211377.g002){ref-type="fig"}).

![A comparison of the serum antibody levels against four purified synthetic peptides between CTEPH patients and HDs.\
The results of the AlphaLISA analyses are shown. The error bars show the mean and standard deviation. n.s.: not significant.](pone.0211377.g002){#pone.0211377.g002}

Correlation between antibodies' titers and clinical parameters in CTEPH patients {#sec013}
--------------------------------------------------------------------------------

We then analyzed correlations between the antibody levels and the clinical data of the patients, including the gender, age, body mass index, symptom duration, and hemodynamic parameters measured by right heart catheter. We found the antibody levels of bEXD2-307 showed a mild negative correlation between the arterial oxygen pressure in CTEPH patients ([Table 4](#pone.0211377.t004){ref-type="table"}) and did decrease after successful pulmonary endarterectomy in CTEPH patients ([Fig 3](#pone.0211377.g003){ref-type="fig"}).

![The pulmonary hemodynamics and the fluctuation in the serum antibody levels against EXD2 and PHAX peptides in patients with CTEPH before and one year after pulmonary endarterectomy (PEA).\
The mean pulmonary artery pressure decreased from 45.5±10.9 to 25.3±7.4 mmHg and the pulmonary vascular resistance decreaseased from 732.0±287.4 to 322.1±157.2 dyne·sec·cm^-5^. The titers of EXD2 also decreased after these successful PEA. n.s.: not significant.](pone.0211377.g003){#pone.0211377.g003}

10.1371/journal.pone.0211377.t004

###### Correlation coefficient between autoantibody titers and clinical parameters in CTEPH patients.

![](pone.0211377.t004){#pone.0211377.t004g}

  Factors                                           Correlation Coefficient   *p* value
  ------------------------------------------------- ------------------------- ---------------------------------------------
  bEXD2-307                                                                   
  Age                                               0.1094                    0.2886
  Symptom duration (months)                         -0.0100                   0.9285
  Mean pulmonary artery pressure (mmHg)             0.1227                    0.2338
  Pulmonary vascular resistance (dyne·sec·cm^-5^)   0.0656                    0.5279
  Cardiac output (L/min)                            0.0220                    0.8313
  Arterial oxygen pressure (mmHg)                   -0.2096                   0.0415 [†](#t004fn001){ref-type="table-fn"}
  Mixed venous oxygen pressure                      -0.1074                   0.3004
  bPHAX-247                                                                   
  Age                                               0.1075                    0.2972
  Symptom duration (months)                         -0.0419                   0.7070
  Mean pulmonary artery pressure (mmHg)             0.0154                    0.8818
  Pulmonary vascular resistance (dyne·sec·cm^-5^)   0.0140                    0.8929
  Cardiac output (L/min)                            0.0165                    0.8732
  Arterial oxygen pressure (mmHg)                   -0.0177                   0.8647
  Mixed venous oxygen pressure                      -0.0130                   0.9003

†: *p* \< 0.05. EXD2: exonuclease 3\'--5\' domain-containing 2; PHAX: Phosphorylated Adaptor for RNA Export.

An exploratory analysis of the autoantibodies in PAH and SAS patients {#sec014}
---------------------------------------------------------------------

As an exploratory analysis, we examined the serum antibody levels for those two purified peptides using another set of sera from patients with PAH. The serum antibody levels to bEXD2-307 and bPHAX-247 were also elevated in patients with PAH, similar to our observations in CTEPH patients. A sub-analysis of sub-groups of PAH revealed that the patients with idiopathic PAH (IPAH) and PAH with connective tissue disease (CTD-PAH) had significantly higher titers for those peptides than HDs ([Fig 4](#pone.0211377.g004){ref-type="fig"}). The antibody levels of bEXD2-307 and bPHAX-247 did not correlate with pulmonary hemodynamics (data not shown). We were able to measure the level of auto-antibody after the treatment with selective pulmonary vasodilator in 17 of the 65 PAH patients (treatment naïve: n = 4, add-on: n = 13; mean treatment period: 33.1±13.5 months). The mean pulmonary artery pressure decreased from 45.3±9.6 to 40.1±13.8 mmHg, but the pulmonary vascular resistance did not decrease. The titers of anti-EXD2 antibody and anti-PHAX antibody did not decrease after the treatment neither ([S1 Fig](#pone.0211377.s001){ref-type="supplementary-material"}).

![A comparison of the serum antibody levels against EXD2 and PHAX peptides among subgroups of PAH and HDs.\
CTD-PAH: PAH with connective tissue disease. Group 1 PAH: congenital heart disease, portopulmonary hypertension. Group 5 PH: pulmonary artery stenosis, aortitis, sarcoidosis. The error bars show the mean and standard deviation.](pone.0211377.g004){#pone.0211377.g004}

We also examined the titers of those 2 auto-antibodies in 80 patients with SAS, another hypoxic condition. Their mean age was 58.7±11.0 years, and the sex ratio (M:F) was 54:26. The apnea/hypopnea index (AHI) in these patients was as follows: mild (5--15) in n = 11, moderate (15--30) in n = 17, and severe (30 or higher) in n = 52. However, there was no significant difference in titers between HDs and SAS patients ([S2 Fig](#pone.0211377.s002){ref-type="supplementary-material"}).

Discussion {#sec015}
==========

We screened for autoantibodies in the sera of CTEPH patients using ProtoArray, which resulted in the selection of 34 candidate antigens ([Table 1](#pone.0211377.t001){ref-type="table"}). We then synthetized 63 crude peptides predicted to be the epitope sites of those 34 candidate antigens ([Table 2](#pone.0211377.t002){ref-type="table"}) and evaluated the titers of the autoantibodies for those peptides by AlphaLISA ([Fig 1](#pone.0211377.g001){ref-type="fig"}). Based on these results, we synthetized the four purified peptides and re-evaluated the titer of the autoantibodies against those four peptides by AlphaLISA. We ultimately found that CTEPH patients had high titers of autoantibodies for exonuclease 3\'-5\' domain-containing 2 (EXD2) and phosphorylated adaptor for RNA export (PHAX) than HDs ([Fig 2](#pone.0211377.g002){ref-type="fig"}). Furthermore, the antibody levels for EXD2 showed a mild negative correlation between the arterial oxygen pressure in CTEPH patients and decreased after successful pulmonary endarterectomy in CTEPH patients ([Fig 3](#pone.0211377.g003){ref-type="fig"}). As an exploratory analysis, we examined the serum antibody levels for those four purified peptides using another set of sera from patients with PAH and SAS. The serum antibody levels to EXD2 and PHAX were also elevated in patients with PAH, similar to our findings in CTEPH patients ([Fig 4](#pone.0211377.g004){ref-type="fig"}). Thus, EXD2 and PHAX may be markers associated with PH in general and not specific to CTEPH.

EXD2 is a 621-amino acid protein with a nuclease domain \[[@pone.0211377.ref015]\]. Its precise role had been unclear; however, Ronan et al. reported that EXD2 is an exonuclease essential for DNA double-strand break (DSB) resection and efficient homologous recombination. EXD2 functionally interacts with the Mre11-Rad50-Nbs1 (MRN) complex to accelerate resection via its 3\'-5\' exonuclease activity, which efficiently processes double-strand DNA substrates containing nicks \[[@pone.0211377.ref016]\]. EXD2 also reportedly has a critical functional link with FANCD2, the gene responsible for Fanconi anemia \[[@pone.0211377.ref015]\]. Fanconi anemia is a severe, congenital form of anemia associated with disorder of DNA repair. It should be noted that the serum anti-EXD2 antibody levels showed mild inverse correlation with arterial oxygen pressure (*p* = 0.0415) ([Table 4](#pone.0211377.t004){ref-type="table"}). DSBs can be induced by ischemia such as anemia and low oxygen pressure \[[@pone.0211377.ref017]\]. Thus, it is possible that EXD2 required for repair of DSBs is expressed to the elevated levels, which may induced the development of its autoantibodies.

PHAX is a key molecule in transporting small nuclear RNA (snRNA) and small nucleolar RNA (snoRNA) from the nucleus to the cytosol. PHAX configures a complex with RNA, CBP80, and CBP20 known as the cap binding complex (CBC), followed by binding with CRM1/RanGTP, which leads to the export of RNA into the cytoplasm \[[@pone.0211377.ref018], [@pone.0211377.ref019]\]. snRNAs and snoRNAs play an essential role in the maturation of mRNAs and rRNAs, respectively \[[@pone.0211377.ref020]\].

As described above, EXD2 and PHAX are reported to be involved in DNA repair and the transportation of snRNA/snoRNA, respectively. The precise mechanisms underlying the production of autoantibodies for these antigens were not determined in the present study; however, the titers of those antigens were elevated in both CTEPH and PAH patients, suggesting that this autoantibody production may share a common etiology in CTEPH and PAH patients, e.g. distal pulmonary artery remodeling or right heart burden. It is reported that oxidative stress and inflammation contribute to vascular remodeling \[[@pone.0211377.ref021]\], and these factors are also known to favor DNA damage \[[@pone.0211377.ref022]\]. Indeed, high levels of DNA damage were reported to occur in PAH lungs and remodeled arteries \[[@pone.0211377.ref023]\] \[[@pone.0211377.ref024]\] \[[@pone.0211377.ref025]\]. These previous findings suggest that PH-induced DNA damage followed by the activation of the DNA repair system might account for the overexpression of these antigens and the resultant development of autoantibodies. Regarding DNA damage, both the polyadenylation and deadenylation of mRNA are markedly affected via CBP80 and CBP20 \[[@pone.0211377.ref026]\]. Thus, the functional roles of EXD2 and PHAX may be interrelated. Further investigations focused on the production of these autoantibodies might give us information on the etiology of CTEPH and PAH as well as prove the utility of these autoantibodies as a new diagnostic tool.

Our study had several limitations. First, as the controls were healthy volunteer donors, potential confounding factors between patients with CTEPH and controls (e.g. the age, BMI, hypertension, diabetes, and hyperlipidemia) were not adjusted in the analysis in the current study. Second, we did not investigate the exact mechanism underlying the autoantibody production, so we were unable to determine the pathological etiology of this phenomenon. Third, this study was performed retrospectively at a single institution in Japan. Additional prospective, multicenter investigations are therefore required.

In conclusion, patients with CTEPH and PAH had higher titers for autoantibodies to EXD2 and PHAX than HDs. These autoantibodies may provide novel useful diagnostic and therapeutic tools for treating those patients.

Supporting information {#sec016}
======================

###### The pulmonary hemodynamics and titers of anti-EXD2/anti-PHAX antibody before and after the treatment with selective pulmonary vasodilator in PAH patients.

The mean pulmonary artery pressure decreased from 45.3±9.6 to 40.1±13.8 mmHg, but the pulmonary vascular resistance did not decrease. The titers of anti-EXD2 antibody and anti-PHAX antibody did not decrease after the treatment neither.

(TIF)

###### 

Click here for additional data file.

###### The titers of anti-EXD2 antibody and anti-PHAX antibody in patients with sleep apnea syndrome.

There was no significant difference in the titers of anti-EXD2 antibody or anti-PHAX antibody between the patients with sleep apnea syndrome and HDs.

(TIF)

###### 

Click here for additional data file.
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